Vitality Biopharma Seeks FDA’s Orphan Drug Status for Cannabinoid Therapy VITA-100
News
Vitality Biopharma is seeking orphan drug designation from the U.S. Food and Drug Administration (FDA) for its targeted cannabinoid therapy, VITA-100, for the treatment of pediatric ulcerative colitis. The FDA grants orphan ... Read more